Traumatic
brain injury (TBI) refers to damage to the brain caused by external physical
trauma as a result of head injury due to factors such as falls, vehicle
accidents, assaults, or sport injuries. The currently available treatment
options for TBI include surgical intervention, intensive care unit support,
medical devices, and pharmacological therapies such as analgesics,
anticonvulsants, and antidepressants. The global Traumatic Brain Injury
Therapeutics Market is estimated to be valued at US$ 3.5 Bn in 2024 and is
expected to exhibit a CAGR of 34%
over the forecast period 2024 to 2031, as highlighted in a new report published
by Coherent Market Insights.
Market key trends:
The increasing incidences of head injuries due to road accidents, falls or
sports injuries have drastically accelerated the cases of TBI over the past few
years. As per studies, almost 60% to 90% of all TBI cases in the United States
are mild TBIs, also known as concussions. About 10% are moderate or severe.
Repeated mild TBI or concussions have been associated with long-term
neurological impairment. Thus, the rising cases of TBI are expected to drive
the demand for effective TBI therapeutics such as drugs to reduce inflammation,
prevent cell death, minimize the effects of brain edema, and improve cognitive
functions during the forecast period. Existing therapeutic options have limited
efficacy and new drugs are under development to address the unmet needs in TBI
treatment. This is further expected to boost the growth of the TBI therapeutics
market.
Segment Analysis
The
global
traumatic brain injury therapeutics market size is segmented by
therapeutic, mechanism of action, distribution channel, and geography. The
therapeutic segment dominates the market and is further segmented into
anti-convulsants, analgesics, anti-depressants, anti-psychotics, and others.
The anti-convulsants segment holds the largest market share owing to rising
cases of seizures post head injuries.
Key Takeaways
The global traumatic brain injury therapeutics market is expected to
witness high growth during the forecast period of 2024 to 2031.
Regional
analysis shows that North America is currently the fastest growing region due
to rising awareness and presence of advanced healthcare facilities in the
region.
Key
players operating in the traumatic brain injury therapeutics market are
Microsoft, IBM, Dynatrace, Datadog, Splunk, New Relic, GitLab, CircleCI,
CloudBees, Snyk, Twistlock, Qualys, Salesforce, SAP, Adobe, Oracle, VMware, Red
Hat, Rancher Labs, Sysdig. The market is highly competitive and players are
focusing on new product launches and strategic collaborations to gain market
share.
Comments
Post a Comment